You are here

Homeopathic Drugs to Undergo a Strict FDA Review in Future

Homeopathic Drugs to Undergo a Strict FDA Review in Future

Published April 27, 2015

A public hearing held recently by the Food and Drug Administration (FDA) took testimony and comments to take its decision regarding regulating the homeopathic medications. The agency has taken this step as many studies and reports have questioned the safety of these medications that are available through drugs stores and natural food shops.

Homeopathy is an alternative medical practice that aims to trigger the body’s natural system of healing. Homeopathy is mainly based on the principle of "like cures like." According to homeopathy theory, a substance that produces similar symptoms in healthy people can cure a disease. The homeopath prescribes highly diluted substances mainly in the tablet form, as homeopathy follows "law of minimum dose." This means the lower the dose of the medication, the greater its effectiveness.

As reported by Cynthia Schneider, director of the Office of Compliance at FDA’s Center for Drug Evaluation and Research (CDER), homeopathy has gained tremendous attention in last few decades. The FDA last reviewed its regulation of homeopathic products in 1988 and since then homeopathy has progressed to a multi-billion dollar industry. Although homeopathic products are popular among people, there is little evidence to support homeopathy as an effective treatment for any specific condition. In addition there have been several reports about toxic effects of these drugs.

According to the critics, homeopathic drugs do not undergo any kind of FDA review in terms of efficacy or safety that conventional drugs or other dietary supplements do. 

FDA has thus taken a step to invite written comments from all interested parties, including, but not limited to, consumers, patients, caregivers, health care professionals, patient groups, and industry. 

To read more information on this public hearing about homeopathic medication visit!documentDetail;D=FDA-2015-N-0540-0001



Scroll to top